Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Meijer, E.; Drenth, J.P.H.; d'Agnolo, H.; Casteleijn, N.F.; Fijter, J.W. de; Gevers, T.J.; ... ; DIPAK Consortium (2014)

Article / Letter to editor

• Polycystic kidney disease (PKD)
• cyst progression
• glomerular filtration rate (GFR)
• kidney volume
• quality of life (QoL)
• disease trajectory
• renal disease
• somatostatin analog

• All authors: Meijer, E.; Drenth, J.P.H.; d'Agnolo, H.; Casteleijn, N.F.; Fijter, J.W. de; Gevers, T.J.; Kappert, P.; Peters, D.J.M.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Torres, V.E.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Gansevoort, R.T.; DIPAK Consortium
• Date: 2014-03-31
• Journal: American Journal of Kidney Diseases
• Volume: 63
• Issue: 3
• Pages: 446 - 455
• DOI: doi:10.1053/j.ajkd.2013.10.011